AAAAAA

   
Results: 1-25 | 26-33

Table of contents of journal:

Results: 1-25/33
Basic principles of antisense technology
Authors: Crooke, ST
Citation: St. Crooke, Basic principles of antisense technology, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 1-28
Medicinal chemistry of antisense oligonucleotides
Authors: Cook, PD
Citation: Pd. Cook, Medicinal chemistry of antisense oligonucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 29-56
Analytical methods for antisense drugs
Authors: Leeds, JM Cummins, LL
Citation: Jm. Leeds et Ll. Cummins, Analytical methods for antisense drugs, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 57-82
A role for antisense technology in the discovery of highly specific and versatile signal transduction inhibitors
Authors: Monia, BP Koller, E Gaarde, WA
Citation: Bp. Monia et al., A role for antisense technology in the discovery of highly specific and versatile signal transduction inhibitors, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 83-105
Methods of selecting sites in RNA for antisense targeting
Authors: Freier, SM
Citation: Sm. Freier, Methods of selecting sites in RNA for antisense targeting, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 107-118
Pharmacokinetic properties in animals
Authors: Geary, RS Yu, RZ Leeds, JM Watanabe, TA Henry, SP Levin, AA Templin, MV
Citation: Rs. Geary et al., Pharmacokinetic properties in animals, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 119-154
Suborgan pharmacokinetics
Authors: Crooke, RM Graham, MJ
Citation: Rm. Crooke et Mj. Graham, Suborgan pharmacokinetics, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 155-182
Pharmacokinetic properties in humans
Authors: Yu, RZ Geary, RS Watanabe, TA Levin, AA Schoenfeld, SL
Citation: Rz. Yu et al., Pharmacokinetic properties in humans, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 183-200
Toxicity of antisense oligonucleotides
Authors: Levin, AA Henry, SP Monteith, D Templin, MV
Citation: Aa. Levin et al., Toxicity of antisense oligonucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 201-267
Clinical safety of phosphorothioate oligodeoxynucleotides
Authors: Dorr, FA Glover, JG Kwoh, TJ
Citation: Fa. Dorr et al., Clinical safety of phosphorothioate oligodeoxynucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 269-290
General pharmacology of phosphorothioate oligodeoxynucleotides
Authors: Bennett, CF
Citation: Cf. Bennett, General pharmacology of phosphorothioate oligodeoxynucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 291-318
Pharmacology of 2 '-O-(2-methoxy)ethyl-modified antisense oligonucleotides
Authors: Dean, NM Butler, M Monia, BP Manoharan, M
Citation: Nm. Dean et al., Pharmacology of 2 '-O-(2-methoxy)ethyl-modified antisense oligonucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 319-338
LNA (locked nucleic acid)
Authors: Wengel, J
Citation: J. Wengel, LNA (locked nucleic acid), ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 339-357
Antisense properties of peptide nucleic acid (PNA)
Authors: Koppelhus, U Nielsen, PE
Citation: U. Koppelhus et Pe. Nielsen, Antisense properties of peptide nucleic acid (PNA), ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 359-374
Phosphorodiamidate morpholino oligomers
Authors: Iversen, P
Citation: P. Iversen, Phosphorodiamidate morpholino oligomers, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 375-389
Oligonucleotide conjugates in antisense technology
Authors: Manoharan, M
Citation: M. Manoharan, Oligonucleotide conjugates in antisense technology, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 391-469
Immune stimulation by oligonucleotides
Authors: Krieg, AM
Citation: Am. Krieg, Immune stimulation by oligonucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 471-515
Pre-mRNA splicing as a target for antisense oligonucleotides
Authors: Kole, R Mercatante, D
Citation: R. Kole et D. Mercatante, Pre-mRNA splicing as a target for antisense oligonucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 517-539
Application of antisense oligonucleotides to the study of CNS protein function
Authors: Ho, SP
Citation: Sp. Ho, Application of antisense oligonucleotides to the study of CNS protein function, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 541-564
Antisense approach to isoform-specific blockade of acetylcholinesterase
Authors: Soreq, HE Seidman, S
Citation: He. Soreq et S. Seidman, Antisense approach to isoform-specific blockade of acetylcholinesterase, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 565-586
Serine/threonine protein phosphatases
Authors: Honkanen, RE
Citation: Re. Honkanen, Serine/threonine protein phosphatases, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 587-614
Pharmacological activities of antisense drugs: Inflammatory diseases
Authors: Karras, JG Myers, KJ Baker, BF
Citation: Jg. Karras et al., Pharmacological activities of antisense drugs: Inflammatory diseases, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 615-678
Respirable antisense oligonucleotides (RASONs)
Authors: Nyce, JW
Citation: Jw. Nyce, Respirable antisense oligonucleotides (RASONs), ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 679-685
Combined antisense therapy and chemotherapy in animal models
Authors: Mercola, D
Citation: D. Mercola, Combined antisense therapy and chemotherapy in animal models, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 687-707
Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease
Authors: Haller, H Maasch, C Dragun, D Wellner, M Luft, FC
Citation: H. Haller et al., Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 709-723
Risultati: 1-25 | 26-33